HC Wainwright initiated coverage on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $7.00 target price on the stock.
Immix Biopharma Trading Up 7.1 %
Shares of IMMX opened at $2.12 on Monday. The firm has a market capitalization of $55.99 million, a P/E ratio of -2.28 and a beta of 0.17. Immix Biopharma has a 12-month low of $1.55 and a 12-month high of $7.75. The firm has a fifty day moving average price of $2.16 and a 200-day moving average price of $3.40.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Analysts predict that Immix Biopharma will post -0.93 earnings per share for the current year.
Institutional Trading of Immix Biopharma
Immix Biopharma Company Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
- Five stocks we like better than Immix Biopharma
- What is a Secondary Public Offering? What Investors Need to Know
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What is the Euro STOXX 50 Index?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is MarketRankā¢? How to Use it
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.